ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2025
Zinzino group revenue increased 46% in Q4 and total revenue for the full year 2025 increased 51%, compared with the previous year.
The revenue in December for Zinzino's sales markets increased by 35 % and amounted to SEK 334.4 (246.9) million. Faun Pharma's external sales decreased and amounted to SEK 2.9 (5.8) million. Overall, the Group increased revenues by 33 % to SEK 337.3 (252.7) million compared with the previous year.
Revenue in Zinzino's sales markets increased by 50 % in the fourth quarter of 2025 compared with the same period last year and amounted to SEK 1,032.3 (690.3) million. Total revenues in the Group increased by 46 % in the fourth quarter and amounted to SEK 1,042.4 (713.5) million.
Accumulated revenue for January – December 2025 increased by 51% to SEK 3,344.5 (2,207.8) million.
Revenues were distributed as follows:
|
Regions, mSEK |
25-Dec |
24-Dec |
Change |
Q4 2025 |
Q4 2024 |
Change |
YTD 2025 |
YTD 2024 |
Change |
|
The Nordics |
31.4 |
29.6 |
6% |
98.4 |
88.0 |
12% |
332.5 |
302.0 |
10% |
|
Central Europe |
102.9 |
78.1 |
32% |
337.9 |
202.3 |
67% |
995.4 |
596.7 |
67% |
|
East Europe |
36.3 |
34.5 |
5% |
122.0 |
120.6 |
1% |
398.0 |
400.4 |
-1% |
|
South & West Europe |
53.7 |
49.7 |
8% |
167.8 |
131.9 |
27% |
565.8 |
396.4 |
43% |
|
The Baltics |
18.0 |
12.0 |
50% |
48.3 |
38.2 |
26% |
133.5 |
107.6 |
24% |
|
North America |
52.0 |
21.1 |
146% |
163.8 |
66.3 |
147% |
545.7 |
200.5 |
172% |
|
Asia-Pacific |
37.4 |
20.2 |
85% |
86.2 |
37.1 |
132% |
299.4 |
84.6 |
254% |
|
Africa |
2.7 |
1.7 |
59% |
7.8 |
5.9 |
32% |
23.8 |
16.8 |
42% |
|
Zinzino |
334.4 |
246.9 |
35% |
1,032.3 |
690.3 |
50% |
3,294.1 |
2,105.0 |
56% |
|
Faun Pharma |
2.9 |
5.8 |
-50% |
10.1 |
23.2 |
-57% |
50.4 |
102.8 |
-51% |
|
Zinzino Group |
337.3 |
252.7 |
33% |
1,042.4 |
713.5 |
46% |
3,344.5 |
2,207.8 |
51% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines, South Korea
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, dag@zinzino.com
Fredrik Nielsen CFO Zinzino +46 (0) 707 900 174, fredrik.nielsen@zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
Certified Adviser: DNB Carnegie Investment Bank AB (publ.)
Zinzino is a global health tech company from Scandinavia, pioneering a new standard in personal health through advanced home health tests and scientifically proven nutritional supplements. Listed on the Nasdaq First North Premier Growth Market, the company’s test-based, personalized nutrition strategy empowers individuals to take charge of their long-term health with science-based insights and targeted solutions. Its third-party validated products are available through direct sales distributors in more than 100 markets worldwide. Zinzino’s headquarters are located in Gothenburg, Sweden, with additional offices across Europe, Asia, and Australia.